Mangrove Partners IM LLC Buys New Shares in ANI Pharmaceuticals, Inc. $ANIP

Mangrove Partners IM LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,587 shares of the specialty pharmaceutical company’s stock, valued at approximately $836,000.

Other large investors also recently modified their holdings of the company. Divisadero Street Capital Management LP purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at $21,454,000. Apis Capital Advisors LLC lifted its stake in shares of ANI Pharmaceuticals by 28.1% during the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after buying an additional 36,000 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after buying an additional 27,598 shares in the last quarter. Oliver Luxxe Assets LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at $1,823,000. Finally, Artemis Investment Management LLP purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at $1,706,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.9%

Shares of ANIP stock opened at $83.00 on Wednesday. The stock has a market cap of $1.89 billion, a P/E ratio of 21.01 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company’s fifty day simple moving average is $80.06 and its two-hundred day simple moving average is $79.40.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of analyst reports. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $82.03, for a total value of $41,015.00. Following the sale, the vice president owned 77,890 shares in the company, valued at $6,389,316.70. The trade was a 0.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares in the company, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 79,016 shares of company stock worth $6,195,991. 8.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.